Adams Street Partners Raises $475 Million Across Venture and Growth Equity Fund Programs

Chicago-based private markets investment firm Adams Street Partners has raked in $475 million of capital across its venture and growth equity fund programs. The firm which focuses on software, enterprise software and biotech deals, says the latest capital injection has brought its capital raised across its strategies to over $2 billion.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Adam Street’s Venture/Growth Team leads investments between $5 million to $30 million in high growth technology and healthcare companies, doling out between $125 million and $150 million annually. The team, made up of nine dedicated investment professionals across its Menlo Park and Chicago offices, specifically targets SaaS, mobile, cloud, security, fintech, healthcare IT, medical device and biopharma startups. ASP’s venture and growth equity arm has an active portfolio of over 50 companies and collectively serves on the board of more than 40 of them.

Earlier this year, the private equity shop brought on Trinity Ventures general partner Fred Wang as the latest partner for ASP Capital.

“We are proud to partner with market-leading entrepreneurs as they continue to drive impressive growth in their businesses,” said Terry Gould, Partner & Head of Direct Investments at Adams Street Partners. “In addition, we are very excited to offer our clients exposure to some of the most innovative companies across the US, European and Israeli markets.”

Founded in 1972, Adam Street Partners operates out of nine locations around the world with investments across over 30 countries. The private investment group manages $30 billion in assets across five strategies – primary and secondary private equity fund investments, co-investments, private credit investments and direct venture/growth investments. The firm’s over 225 investments include a number of leading companies such as Paylocity (PCTY), BrightRoll (YHOO), INC Research (Avista) and Criteo (CRTO).